Skip to main content
SpringerLink
Log in

TNF: A brief review with emphasis on its antitumor activity

  • Published:
Biotherapy

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666–70.

    Google Scholar 

  2. Warren SJ, Ward PA, Johnson KJ. Tumor necrosis factor: a plurifunctional mediator of acute inflammation. Mod Pathol 1988; 1: 242–7.

    Google Scholar 

  3. Leibovich SJ, Polverine PJ, Shephard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-alpha. Nature 1987; 329: 630–2.

    Google Scholar 

  4. Parant M. Effects of TNF in bacterial infections. Ann Inst Pasteur Immunol 1988; 139: 301–4.

    Google Scholar 

  5. Vilcek J, Paslombella VJ, Zhang Y, Lin JX, Feinman R, Reis LFL, Le J. Mechanisms and significance of the mitogenic and antiviral actions of TNF. Ann Inst pasteur Immunol 1988; 139: 307–11.

    Google Scholar 

  6. Sung SJ, Bjorndahl JM, Wong CY, Kao HT, Fu SM. Production of tumor necrosis factor/cachectin by human T-cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody. J Exp Med 1988; 167: 937–53.

    Google Scholar 

  7. Mannel DM, Moore RN, Mergenhagen SE. Macrophages as a source of tumoricidal activity (tumor necrotizing factor). Infect Immunol 1980; 30: 523–30.

    Google Scholar 

  8. Beutler B, Greenwold D, Hulmes JD, Change M, Pan YCE, Mathison J, Ulevitch R, Cerami A. Identity of tumor necrosis factor and the macrophage secreted factor cachectin. Nature 1985; 316: 552–4.

    Google Scholar 

  9. Caput D, Beutler B, Hartog K, Brown-Schnemer S, Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci (Wash) 1986; 83: 1670–4.

    Google Scholar 

  10. Shimamoto Y, Chen RL, Bollon A, Chang A, Khan A. Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock. Immunol Letters 1988; 17: 311–8.

    Google Scholar 

  11. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355.

    Google Scholar 

  12. Nio Y, Zighelboim J, Berck JS, Bonavida B. Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK432. Cancer Immunol Immunother 1988; 27: 246–54.

    Google Scholar 

  13. Fransen L, Ruysschaert MR, Van der Heyden J, Fiers W. Recombinant tumor necrosis factor: species specificity for a variety of human and murine transformed cell lines. Cell Immunol 1986; 100: 260–7.

    Google Scholar 

  14. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM. Recombinant human tumor necrosis factor a: effects on proliferation of normal and transformed cellsin vitro. Science 1985; 230: 943–5.

    Google Scholar 

  15. Fransen L, Van der Heyden J, Ruysschaert R, Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986; 22: 419–26.

    Google Scholar 

  16. Suffys P, Beyaert R, Van Roy F, Fiers W. TNF in combination with interferon gamma is cytotoxic to normal untransformed mouse and rat embryo fibroblast like cells. Anticancer Res 1989; 9: 167–71.

    Google Scholar 

  17. Digel W, Stefanic M, Schoniger W, Buck C, Raghavachar A, Frickhoven N, Heimpel H, Porzsolt F. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 1989; 73: 1242–6.

    Google Scholar 

  18. Watanabe N, Neda H, Ohtusuka Y, Sone H, Yamauchi N, Maeda M, Kuriyama H, Niitsu Y. Signalling pathway of tumor necrosis factor in normal and tumor cells. Cancer Immunol immunother 1989; 28: 157–63.

    Google Scholar 

  19. Rubin BY, Smith LJ, Hellermann GR, Lunn RM, Richardson NK, Anderson SL. Correlation between the anticellular and DNA fragmenting activities of tumor necrosis factor. Cancer Res 1988; 48: 6006–10.

    Google Scholar 

  20. Matthews N, Neale ML, Jackson SK, Stork JM. Tumor cell killing by tumor necrosis factor: inhibition by anaerobic conditions, free radical scavengers, and inhibitors of arachidonate metabolism. Immunology 1987; 62: 153–5.

    Google Scholar 

  21. Wong GHW, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science (Wash. DC) 1988; 242: 941–4.

    Google Scholar 

  22. Zimmerman RJ, Chan A, Leadon SA. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res 1989; 49: 1644–8.

    Google Scholar 

  23. Darzynkiewitcz Z, Carter SP, Old LJ. Effect of recombinant tumor necrosis factor on HL-60 cells: Cell-cycle specificity and synergism with actinomycin-D. J Cell Physiol 1987; 130: 328–35.

    Google Scholar 

  24. Talmadge JE, Black PL, Tribble H, Pennington R, Bowersox O, Schneider M, Phillips H. Preclinical approaches to the treatment of metastatic disease: therapeutic properties of RH TNF, RM IFNgamma, and RH IL-2. Drugs Exptl Clin Res 1987; 13: 327–37.

    Google Scholar 

  25. Asher A, Male JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138: 963–74.

    Google Scholar 

  26. Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984; 34: 263–7.

    Google Scholar 

  27. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 1986; 46: 3990–3.

    Google Scholar 

  28. Miki T, Kotake T. Anti-cancer drug sensitivity test against human testicular cancer xenograft-comparison with clinical results of chemotherapy. Hinyokika kiyo 1988; 34(11): 1903–9 (abstract english).

    Google Scholar 

  29. Marquet RL, Westbroek DL, Jeekel J. Interferon treatment of a transplantable colon adenocarcinoma; importance of tumor site. Int J Cancer 1984; 33: 689–92.

    Google Scholar 

  30. Marquet RL, Uzermans JNM, De Bruin RWF, Fiers W, Jeekel J. Anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) on colon cancer in rats is promoted by recombinant rat interferon gamma; toxicity is reduced by indomethacin. Int J Cancer 1987; 40: 550–3.

    Google Scholar 

  31. Scheringa M, Keizer A, Jeekel J, Marquet RL. Anti-tumor effect of recombinant murine TNF-alpha (rMuTNFa) given by continuous iv infusion as compared to repeated iv injections in a rat liver metastasis model. Int J Cancer 1989; 43: 905–9.

    Google Scholar 

  32. IJzermans JNM, De Bruin RWF, Marquet RL, Jeekel J. The efficacy of tumor necrosis factor is enhanced by concomitant treatment with the interferon inducer bropirimine. Eur Surg Res 1988; 20: 41.

    Google Scholar 

  33. Havell EA, Fiers W, North RJ. The antitumor function of tumor necrosis factor (TNF) I. J Exp Med 1988; 167: 1067–85.

    Google Scholar 

  34. Satomi N, Sakurai A, Haranaka R, Haranaka K. Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor. J Biol Res Mod 1988; 7: 54–64.

    Google Scholar 

  35. Schiller JH, Bittner G, Storer B, Willson KV. Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines. Cancer Res 1987; 47: 2809–13.

    Google Scholar 

  36. Van der Heyden J, Fransen L, Fiers W. Treatment of murine interferon a/b-sensitive and resistant friend leukemia cells with tumor necrosis factor in combination with murine interferon a/b or gamma. J Interferon Res 1986; 6: 633–8.

    Google Scholar 

  37. Ruggiero V, Tavernier J, Fiers W, Baglioni C. Induction of the synthesis of tumor necrosis factor receptors by interferon gamma. J Immunol 1986; 136: 2445–50.

    Google Scholar 

  38. Inugawa H, Sshima H, Soma G, Mizuno D. TNF induces endogenous TNFin vivo: the basis of EET therapy as a combination of rTNF together with endogenous TNF. J Biol Res Mod 1988; 7: 596–607.

    Google Scholar 

  39. Palladino MA, Figari IS.In vivo anti-tumor activity of recombinant human tumor necrosis factor-alpha against Meth—A sarcoma requires L3T4-positive cells. Ann Inst Pasteur Immunol 1988; 139: 299–301.

    Google Scholar 

  40. Talmadge JE, Phillips H, Schneider M, Rowqe T, Pennington R, Bowersox O, Lenz B. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988; 48: 544–50.

    Google Scholar 

  41. Shan H. Cytostatic and tumoricidal activities of tumor necrosis factor treated neutrophils. Immunology Letters 1988; 17: 47–51.

    Google Scholar 

  42. Gamble JR, Harlan JM, Klenbanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82:8667–71.

    Google Scholar 

  43. Wankowicz Z, Megyeri P, Issekutz A. Synergy between tumor necrosis factor alpha and interleukin 1 in the induction of polymorphonuclear leucocyte migration during inflammation. J Leucocyte Biol 1988; 43: 349–56.

    Google Scholar 

  44. Ostersen ME, Thiekle DL, Lipsky PE. Tumor necrosis factor alpha enhances cytolytic activity of human natural killer cells. J Immunol 1987; 138: 4185–91.

    Google Scholar 

  45. Owen-Schaub LB, Gutterman JU, Grimm EA. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res 1988; 48: 788–92.

    Google Scholar 

  46. Scheurich, P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T-cells and TNF-a mediated enhancement of T-cell responses. J Immunol 1987; 138: 1786–90.

    Google Scholar 

  47. Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblastsin vitro. Proc Natl Acad Sci USA 1986; 83: 446–50.

    Google Scholar 

  48. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740–5.

    Google Scholar 

  49. Shimomura K, Manda T, Mukumoto S, Kobayashi K, Nakano K, Mori J. Recombinant human tumor necrosis factor alpha: thrombus formation is a cause of anti-tumor activity. Int J Cancer 1988; 41: 243–7.

    Google Scholar 

  50. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E, Dufe DW. Recombinant human tumor necrosis factor administered as a five day continuous infusion in cancer patients: phase 1 toxicity and effects on lipid metabolism. J Clin Oncol 1988; 6: 344–50.

    Google Scholar 

  51. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase 1 study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986–9.

    Google Scholar 

  52. Bartsch HH, Pfizenmaier K, Schroeder M, Nagel GA. Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. Eur J Cancer Clin Oncol 1989; 25: 287–91.

    Google Scholar 

  53. Padavic P, Otterey F, Rudolph A, Comis R. Metabolic changes in patients treated in a phase 1 trial of recombinant tumor necrosis factor (rTNF). Immunol Proc AACR 1988; 29.

  54. Creaven PJ, Brenner DE, Cowens JW, Huben RP, Wolf RM, Takita H, Arbuck SG, Razack MS, Proefrock AD. A phase 1 clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 1989; 23: 186–91.

    Google Scholar 

  55. Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys, Shiga T. Tumor necrosis factor in man: clinical and biological observations. Br J Cancer 1987; 56: 803–8.

    Google Scholar 

  56. Conkling PR, Chau CC, Nadler P, Greenberg CS, Doty E, Misukonis MA, Haney AF, Bast RC, Weinberg JB. Clinical trials with human tumor necrosis factor:in vivo andin vitro effects on human mononuclear phagocyte function. Cancer Res 1988; 48: 5604–9.

    Google Scholar 

  57. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A phase 1 clinical trial of recombinant human tumor necrosis factor. Cancer 1988; 62: 2467–71.

    Google Scholar 

  58. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase 1 trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6: 1328–34.

    Google Scholar 

  59. Chapman PB, Lester TJ, Casper ES, Gabrilove, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HE Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J. Clin Oncol 1987; 5: 1942–51.

    Google Scholar 

  60. Pfreundschuh MG, Steinmetz HT, Tueschen R, Schenk V, Diehl V, Schaadt M. Phase 1 study of intratumoral application of recombinant human tumor necrosis factor. Eur J Cancer Clin Oncol 1989; 25: 379–88.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory for Experimental Surgery, Erasmus University, PO Box 1738, 3000, DR Rotterdam, The Netherlands

    M. Scheringa & R. L. Marquet

Authors
  1. M. Scheringa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. L. Marquet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheringa, M., Marquet, R.L. TNF: A brief review with emphasis on its antitumor activity. Biotherapy 2, 275–281 (1990). https://doi.org/10.1007/BF02173530

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02173530

Keywords

Search

Navigation